No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...

Please provide your email address to receive an email when new articles are posted on . The human monoclonal antibody denosumab more effectively increases bone mass in patients with low bone mineral ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Denosumab and bisphosphonates exhibit similar efficacy and safety profiles for preventing fractures among patients with osteoporosis. Evidence from a large population-based cohort study in South Korea ...

SAN FRANCISCO, CA—Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, ...

Credit: Shutterstock. Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types. Treatment with denosumab (Prolia ®) was associated with ...

Based on the results of a non-inferiority study, in January 2018 the U.S. Food and Drug Administration (FDA) approved the use of denosumab for the prevention of skeletal events in patients with ...

SEATTLE -- Risk of death was lower in the years after a bisphosphonate was started following a fracture rather than denosumab (Prolia), a target trial emulation found. In adults ages 50 and older who ...

Denosumab, a fully human antibody against receptor activator of NF-κB ligand, and alendronate, a bisphosphonate, have different mechanisms of action in preventing structural decay of bone in patients ...